for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Urogen Pharma Ltd

URGN.OQ

Latest Trade

35.50USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

30.60

 - 

55.03

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
35.50
Open
--
Volume
--
3M AVG Volume
4.56
Today's High
--
Today's Low
--
52 Week High
55.03
52 Week Low
30.60
Shares Out (MIL)
20.90
Market Cap (MIL)
757.34
Forward P/E
-7.33
Dividend (Yield %)
--

Next Event

Urogen Pharma Ltd Corporate Analyst Meeting

Latest Developments

More

Urogen Pharma Reports Q2 Loss Per Share $1.08

Urogen Pharma Reports Q1 Loss Per Share $1.11

Urogen Pharma Qtrly Shr Loss $1.46

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Urogen Pharma Ltd

Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC). Its other clinical-stage drug candidates include Vesimune and BotuGel. Vesimune is a formulation of the toll-like receptor7 (TLR7) agonist Imiquimod for local intravesical delivery for the treatment of Carcinoma In-Situ. BotuGel is an intravesical sustained release formulation of botulinum toxin for Overactive Bladder (OAB) and Interstitial Cystitis (IC). Its platform technologies include: RTGel and Immunotherapy.

Industry

Biotechnology & Drugs

Contact Info

9 Ha'Ta'asiya St

+972.9.7707601

http://www.urogen.com

Executive Leadership

Arie S. Belldegrun

Chairman of the Board

Elizabeth A. Barrett

President, Chief Executive Officer, Director

Peter P. Pfreundschuh

Chief Financial Officer

Gil Hakim

President - Israeli Operation

Stephen Mullennix

Chief Operating Officer

Key Stats

1.67 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2017

-2.140

2018

-4.800

2019(E)

-4.944
Price To Earnings (TTM)
--
Price To Sales (TTM)
2,516.07
Price To Book (MRQ)
3.36
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-51.82
Return on Equity (TTM)
-48.97

Latest News

BRIEF-Urogen Pharma Appoints Elizabeth Barrett As President And CEO

* UROGEN PHARMA - APPOINTS ELIZABETH BARRETT AS PRESIDENT AND CEO

INTERVIEW-Israel's UroGen to start mid-stage bladder cancer trial

Israel's UroGen Pharma plans to begin a mid-stage trial of its treatment for bladder cancer patients in August, after positive interim results last month from an advanced trial of a treatment for upper urinary tract cancer.

BRIEF-Urogen Pharma Announces Positive Interim Results From Pivotal Phase 3 Olympus Trial Of UGN-101

* UROGEN PHARMA ANNOUNCES POSITIVE INTERIM RESULTS FROM PIVOTAL PHASE 3 OLYMPUS TRIAL OF UGN-101 (MITOGEL™) FOR NON-SURGICAL TREATMENT OF UPPER TRACT UROTHELIAL CANCER (UTUC)

BRIEF-UroGen Pharma Reports Q1 Loss Per Share Of $0.88

* UROGEN PHARMA REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND RECENT CORPORATE DEVELOPMENTS

BRIEF-Urogen Pharma Reports Q4 Loss Per Share Of $0.74

* UROGEN REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Urogen Pharma Announces Pricing Of Public Offering Of Ordinary Shares

* UROGEN PHARMA ANNOUNCES PRICING OF PUBLIC OFFERING OF ORDINARY SHARES

BRIEF-Urogen Announces Proposed Public Offering Of Ordinary Shares

* UROGEN PHARMA ANNOUNCES PROPOSED PUBLIC OFFERING OF ORDINARY SHARES

BRIEF-Urogen Pharma Q3 loss per share $0.02

* Urogen Pharma reports third quarter 2017 financial results and recent corporate developments

BRIEF-Menora Mivtachim reports 5.38 pct passive stake in UroGen Pharma

* Menora Mivtachim Holdings Ltd reports 5.38 percent passive stake in UroGen Pharma Ltd as of Nov 1 - SEC filing Source: (http://bit.ly/2hdmj4k) Further company coverage:

BRIEF-Urogen Pharma receives FDA fast track designation for Mitogel

* Urogen Pharma receives FDA fast track designation for Mitogel for the treatment of upper tract urothelial carcinoma (UTUC)

BRIEF-UroGen Pharma Q2 loss per share $0.70

* UroGen Pharma reports second quarter 2017 financial results and recent corporate developments

BRIEF-Jay Moorin reports a 11.5 pct passive stake in Urogen Pharma

* Jay Moorin reports a 11.5 percent passive stake in Urogen Pharma Ltd as of May 9, 2017 - SEC filing Source text for Eikon: (http://bit.ly/2ufDxWd) Further company coverage:

BRIEF-Allergan submits investigational NDA for rtgel in combination with botox

* Investigational new drug application for rtgel™ in combination with botox® for the treatment of overactive bladder submitted to FDA by Allergan

BRIEF-Arkin Communications reports 13.32 pct stake in Urogen Pharma Ltd as on May 4, 2017

* Arkin Communications Ltd reports a 13.32 percent stake in Urogen Pharma Ltd as on May 4, 2017 - sec filing Source text (http://bit.ly/2qxuprm) Further company coverage:

BRIEF-Urogen Pharma announces closing of initial public offering

* Urogen Pharma announces closing of initial public offering and exercise of underwriters' option Source text for Eikon: Further company coverage:

BRIEF-Urogen Pharma says initial public offering of 4.47 mln common shares priced at $13 per share

* Says initial public offering of 4.47 million common shares priced at $13.00per share Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up